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CHAPTER 3
THE INCIDENCE OF VENOUS THROMBOEMBOLISM
IN RELATIVES OF PATIENTS WITH
THE PROTHROMBIN 20210A MUTATION
- an interim analysis -
Saskia Middeldorp, Johan R. Meinardi, Maria M.W. Koopman,
Jan van der Meer, Elisabeth C.M. van Pampus, Karly Hamulyák,
Martin H. Prins, and Harry R. Büller
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SUMMARY
Background: The prothrombin 20210A mutation is a genetic defect associated with elevated
levels of prothrombin and an increased risk for venous thromboembolism. When the absolute
incidence of venous thromboembolism in relatives of patients known to have the mutation
outweighs the disadvantages of prophylactic strategies, family screening may be necessary.
Methods: To determine the incidence of venous thromboembolism in carriers of the
prothrombin 20210A mutation, we retrospectively studied 155 first-degree relatives of 42
heterozygous symptomatic carriers of the prothrombin 20210A mutation. Before DNA
testing, information on previous venous thromboembolism and concomitant risk factors was
obtained. Relatives with and without prothrombin 20210A mutation were compared.
Results: The annual incidence of thromboembolism in relatives of heterozygous propositi
was 0.40% (95% CI 0.18-0.75) in those with the mutation and 0.28% (95% CI 0.10- 0.60) in
those without the mutation (relative risk, 1.4 [95% CI 0.5-4.0]). 
Conclusions: This interim analysis was limited by the small number of observation years and
exposures to exogenous risk factors that could be studied. The absolute incidence of venous
thromboembolism in carriers of the prothrombin 20210A mutation seems to be comparable
to that found in carriers of the factor V Leiden mutation. However, more families need to be
included and the findings should be validated in prospective cohort studies.
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3.1 INTRODUCTION
In recent years, relatively common genetic abnormalities leading toward a tendency for
developing venous thromboembolism have been identified. Until 1994, only isolated
deficiencies of physiologic inhibitors of the coagulation system, such as antithrombin,
protein C, and protein S, were known as established hereditary risk factors and could be
detected in about 8% of consecutive patients with documented venous thromboembolism [1].
In 1993, resistance to activated protein C, most often caused by the FV:Q506 or factor V
Leiden mutation, was shown to be a prevalent risk factor for venous thromboembolism [2-4].
In 1996, the prothrombin 20210A mutation was found to be associated with elevated plasma
concentrations of prothrombin, as well as an increased risk for venous thromboembolism [5].
The prevalence of this mutation in consecutive patients with venous thromboembolism is
approximately 5% [5-7], and in selected patients this may be as high as 18% [5]. The
geographic distribution of the prothrombin 20210A mutation varies, with a prevalence of
about 1-2% in European populations, and much lower in individuals of Asian or African
descent [8, 9]. The relative  risk for venous thromboembolism in heterozygous carriers of the
prothrombin 20210A mutation compared with healthy controls is approximately 3 [5, 6, 10]. 
Because of the autosomal dominant inheritance pattern of the prothrombin 20210A
allele, half of the relatives of each patient who has thrombosis and the mutation will carry the
same defect. Therefore, in clinical practice, the question arises whether families of patients
known to have the prothrombin 20210A mutation should be actively screened for the
presence of the mutation in order to consider instituting prophylactic anticoagulant
strategies, either permanently or during high-risk situations. Disadvantages of screening
include the psychological stress induced among carriers, the risks associated with the pre-
vention of thrombosis by using anticoagulant medication, and the potential problems with
obtaining insurances and social security benefits.
Whether the benefits of screening outweigh the disadvantages, depends largely on the
absolute risk for venous thromboembolism in carriers of the prothrombin 20210A mutation.
This risk needs to be weighed against the known benefits and hazards of anticoagulant
prophylaxis. We therefore investigated 155 first-degree relatives of 42 patients seen at our
institutions with documented venous thromboembolism and the prothrombin 20210A
mutation. From all these relatives, we obtained a medical history with special emphasis on
previous episodes of venous thromboembolism and the exposure to risk factors such as
surgery, trauma, immobilization, pregnancy and the use of oral contraceptives. We then
determined the presence or absence of the prothrombin 20210A mutation and compared the




3.2.1 Patients and study design
In the participating centers, all patients with a proven episode of venous thromboembolism
are tested for the presence of an underlying coagulation disorder. A total of 42 thrombosis
patients with known carriership of the prothrombin 20210A mutation were invited to parti-
cipate in this project and were considered propositi.
All living first-degree relatives (parents, siblings and children older than 15 years of
age), identified through pedigree analysis, formed the study cohort. Each family member was
interviewed by one of the investigators using a standardized medical history form. Detailed
information was obtained about previous episodes of venous thromboembolism, and
exogenous risk factors such as surgical interventions, trauma, periods of immobilization and
prophylactic or therapeutic use of anticoagulant drugs. For women, the obstetric history and
the use of oral contraceptives were documented. Subsequently, blood was obtained and the
prothrombin 20210A mutation status (normal, heterozygous, and homozygous) was
determined by using a polymerase chain reaction-based assay, as described previously [11].
The institutional review boards of the participating centers approved the study, and all
participants gave informed consent.
3.2.2 Definitions
A previous episode of venous thromboembolism was considered to have occurred, if it had
been confirmed by venography, ultrasonography, impedance plethysmography, ventilation-
perfusion lung scanning, or pulmonary angiography. When no objective testing had been
done, but the patient had received full-dose intravenous heparin therapy or vitamin K anta-
gonists for at least 3 months, he or she was considered to also have experienced a venous
thromboembolic event. When required, the patients' charts were reviewed.
Episodes of increased risk for venous thromboembolism included surgery, trauma,
immobilization for more than 7 days, pregnancy, and use of oral contraceptives. An episode
of venous thromboembolism was considered to be related to such a risk situation when it
occurred within 3 months. A relation with use of oral contraceptive use was defined as an
event occurring during exposure to oral contraceptives. Observed years are all years since
the age of 15 years until inclusion in the study or until the date of the first venous
thromboembolic event; this time period was chosen because it was considered to reflect the
duration of exposure to the risk for venous thromboembolism. The information from the
medical history (and, if necessary from other sources) was classified without knowledge of
the prothrombin 20210A status.
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3.2.3 Statistical analysis
The overall and age-specific annual incidence of a first episode of venous thromboembolism
was calculated in relatives with and those without the prothrombin 20210A mutation by
dividing the number of symptomatic family members by the observed years. The relative risk
for the development of a first episode of venous thromboembolism (adjusted for extremes if
necessary) was calculated by dividing the incidence of venous thrombosis in family members
with the mutation by the incidence in family members with the normal genotype. The 95%
CIs were calculated according to normal approximation of the binomial distribution. The
relative  risk (and its mid-P corrected 95% CI) for pregnancy-, and surgery-related venous
thromboembolism was calculated by using a Cox model. For this purpose, a risk period was
considered as an unit of time, and persons who had not had a thromboembolic event by the
end of their last risk period were considered to be censored. If a relative had had an episode
of venous thromboembolism, all subsequent high risk situations were excluded from the
analysis to avoid enhancing risk and because anticoagulant prophylaxis is often given after
such an episode.
3.3 RESULTS
The pedigrees of the 42 propositi with documented venous thromboembolism and the
prothrombin 20210A mutation revealed 276 first-degree family members. Nineteen relatives
were younger than 15 years of age. Furthermore, 42 relatives had died prior to start of the
study. Two of these died of fatal pulmonary embolism. Another 22 relatives were unavailable
because they lived outside of the Netherlands. Finally, 38 relatives could not participate for
various reasons, including reluctance to undergo assessment of genetic disorders, refusal to
give consent, and the presence of terminal diseases. Thus, a total of 155 first-degree family
members were available for the present analysis (response rate of living family members,
66%; overall response rate, 56%).
Approximately half of the 155 relatives carried the prothrombin 20210A mutation
(Table 3.1). Of the 81 family members with the mutation, 3 were found to be homozygous.
Six family members without the mutation and 9 family members with the mutation reported
to have experienced an episode of venous thromboembolism. In the group without the
mutation, 2 individuals suffered from pulmonary embolism, whereas 4 had had deep venous
thrombosis. In the relatives with the mutation, these figures were 2 and 7, respectively. The
absolute annual incidence of a first episode of venous thromboembolism was 0.28% (95%
95% CI 0.10% to 0.60%) in the group with a normal genotype and 0.40% (95% CI 0.18% to
0.75%) in those with the mutation. Thus, the relative  risk for a first episode of venous
thromboembolism among family members with the prothrombin 20210A mutation was 1.4
(95% CI 0.5 to 4.0). In the family members with a normal genotype the
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gender distribution was equal, while 2 of the 6 relatives with thrombosis were men. In the
family members with the mutation, two-thirds were female, and of the 9 relatives with
thrombosis, 7 were women. Two of the 9 symptomatic relatives belonged to the same family
and were found to be homozygous. One was a woman who experienced a pulmonary
embolism 3 days postpartum at the age of 26 years; she also had spontaneous deep-vein
thrombosis two years later, but remained without venous thromboembolic complications in
the next 40 years. The other homozygous relative was her brother who suffered from his first
spontaneous deep venous thrombosis of the leg at the age of 70 years. All 6 relatives in the
group without the prothrombin 20210A mutation had a single episode of thrombosis,
whereas recurrent episodes of venous thromboembolism occurred in 2 of the 9 relatives with
the mutation, one spontaneously and the other postpartum.
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Table 3.2 shows the age-specific annual incidences of a first episode of thrombosis in
relatives with a normal genotype and in those with the mutation. The absolute annual
incidence in the age group of 15 to 30 years with the mutation was 0.57% (95% CI 0.2% to
1.2%), with a relative risk of 5.6 (95%CI 0.7 to 46.3) as compared with their family
members without the mutation. In the age group of 30 to 45 years with the mutation no
thromboembolic complications were reported. In the affected relatives aged 45 to 60 years,
and those older than 60 years, the annual incidences of venous thromboembolism were
0.26% (95%CI 0.006% to 1.4%) and 1.64% (95%CI 0.2% to 5.8%), respectively.
In the group with the mutation, about half of the thrombotic episodes occurred
spontaneously, whereas in the group with a normal genotype, two-thirds of the episodes were
provoked by exogenous risk factors (Table 3.3). The absolute annual incidence of venous
thrombosis among women who had the mutation and used oral contraceptives was lower than
in the women without the mutation (0.2% [95% CI 0.1% to 1.0%] and 0.9% [95% CI 0.1% to
3.2%], respectively), although this difference was not statistically significant. No pregnancy-
related episodes of venous thromboembolism occurred in the group with the normal
genotype; in the group with the prothrombin 20210A mutation, 3 of 80 pregnancies were
complicated by venous thromboembolism. All these episodes occurred in the postpartum
period. In the group without the mutation, 2 out of 77 exposures to sur-
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gery, immobilization, or trauma were complicated by venous thromboembolism, while in
those with the mutation, 1 out of 115 risk episodes was complicated by thrombosis.
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3.4 DISCUSSION
Our preliminary findings suggest that a first-degree relative of a symptomatic heterozygous
propositus who also carries the prothrombin 20210A mutation has an absolute annual risk for
a first episode of venous thromboembolism of 0.40% (95% CI 0.18% to 0.75%) (Table 3.1).
This rate is comparable to that observed in carriers of the factor V Leiden mutation, which
was found to be about 0.45% annually [12, 13]. Unexpectedly, the incidence in the relatives
without the prothrombin 20210A mutation was found to be 0.28% (95% CI 0.10% to
0.60%), which is about 2 to 3 times higher than the reported population risk [14]. As a result,
the relative  risk for venous thromboembolism in the present study was estimated to be 1.4
(95% CI 0.5-4.0) in carriers, as compared with their non-affected family members.
Assuming that the observed rate in the family members without the prothrombin
20210A mutation is erroneously high, and would be closer to 0.1% per year, the relative risk
may become about 4, which is consistent with earlier observations [5, 6, 10]. Why the rate in
noncarriers is so high, is not fully understood, but may be the result of the inclusion of
selected families, who potentially have combined defects that are yet unknown. Since the
response rate of relatives at the time of the present analysis was only 66%, preferential
investigation of symptomatic relatives may have also occurred, although it is likely that this
effect would also be present in the group with the mutation.
Finally, the increased rate may be the result of chance due to the small sample size.
Analysis of the age-specific incidences is also hampered by the small numbers per age group.
It is interesting to note, however, that the relative risk for venous thromboembolism in
carriers of the prothrombin 20210A mutation in the younger age group (15 to 30 years) is
5.6 (95% CI 0.7-46.3), as compared with noncarriers. Half of the thrombotic episodes in
carriers in this age group were related to pregnancies. This observation is in agreement with
earlier findings that a genetic predisposition in women, in combination with the exposure to
increased levels of estrogen (either pregnancy-related or during the use of oral contra-
ceptives) leads to the occurrence of venous thromboembolism at a younger age [15-17].
However, the relationship with the prothrombin 20210A mutation and oral contra-ceptive use
in the present study is yet not clear. 
In order to draw definite conclusions about the absolute risk of venous thrombo-
embolism in carriers of the prothrombin 20210A mutation, both spontaneously and in
relation with exogenous risk factors, more families need to be included and the findings
should be validated in prospective cohort studies.
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